Gosset Ownership
Private
Employees
~51
Therapeutic Areas
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Pure Biologics General Information
Pure Biologics has initiated patient recruitment for a Phase 0 clinical study in project PB003G. The company’s pipeline includes preclinical and early-stage programs focused on novel antibody and aptamer-based therapies targeting immuno-oncology and rare autoimmune/neurological indications. No late-stage or commercialized products reported as of May 2025
Contact Information
Drug Pipeline
PBA-0405
Phase 0Key Partnerships
Not specifically listed by name in public sources; the company collaborates with pharmaceutical and biotechnology companies via contract research services
Pure Biologics Funding
No funding data available
To view Pure Biologics's complete valuation and funding history, request access »